MAM
RETA

Martingale Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Martingale Asset Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,202
Closed -$346K – 1006
2017
Q4 		$346K Sell
12,202
-2,899
-19% -$80.9K ﹤0.01% 874
2017
Q3 		$470K Buy
+15,101
New +$454K 0.01% 850

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Martingale Asset Management's RETA Position: Q1 2018 in Review

Martingale Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2018, closing a stake of 12,202 shares — an estimated $346K sold.

Martingale Asset Management first reported a position in RETA in Q3 2017 and held it in 2 quarters. The position peaked at $470K in Q3 2017. 86 funds tracked by Wall St. Rank hold RETA as of Q1 2018.

  • Martingale Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2018 after selling out during the quarter.
  • Martingale Asset Management sold 12,202 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2018, an estimated $346K.
  • Martingale Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 2 quarters.
  • Martingale Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $470K in Q3 2017.
  • 86 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2018.

Based on Martingale Asset Management's 13F filing for Q1 2018, filed 11 May 2018.